Profile data is unavailable for this security.
About the company
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicines. Its vaccine portfolio includes more than 20 vaccines that help protect people from a range of diseases and infections throughout their lives. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease (COPD), antibiotics, and medicines for skin diseases. It has a global network of about 12 vaccine manufacturing sites.
- Revenue in GBP (TTM)29.09bn
- Net income in GBP4.34bn
- Incorporated1999
- Employees69.40k
- LocationGSK plc980 Great West RoadBRENTFORD TW8 9GSUnited KingdomGBR
- Phone+44 208 047 5000
- Fax+44 208 047 7807
- Websitehttps://www.gsk.com/
More ▼
Mergers & acquisitions
| Acquired company | GSK:LSE since announced | Transaction value |
|---|---|---|
| BELLUS Health Inc | -7.91% | 1.87bn |
| Affinivax Inc | -35.55% | 3.30bn |
Data delayed at least 20 minutes, as of May 26 2023 18:03 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UCB SA | 4.79bn | 364.90m | 14.04bn | 8.70k | 38.52 | 1.74 | 16.00 | 2.93 | 2.16 | 2.15 | 28.69 | 47.81 | 0.3669 | 1.88 | 4.82 | 633,919.30 | 2.79 | 6.23 | 3.48 | 7.82 | 69.66 | 73.49 | 7.61 | 14.76 | 0.7702 | 9.12 | 0.2424 | 31.62 | -4.50 | 4.02 | -60.19 | -11.00 | 12.16 | 2.42 |
| argenx SE | 491.34m | -414.22m | 18.09bn | 843.00 | -- | -- | -- | 36.81 | -8.64 | -8.64 | 10.30 | -- | -- | -- | -- | 670,855.20 | -- | -21.60 | -- | -24.30 | 92.35 | -- | -84.30 | -188.60 | -- | -- | -- | -- | -17.40 | 58.50 | -73.81 | -- | 204.62 | -- |
| Merck KGaA | 19.40bn | 2.82bn | 18.54bn | 64.01k | 22.17 | 2.75 | 4.21 | 0.956 | 7.45 | 7.45 | 51.32 | 60.14 | 0.4707 | 1.88 | 5.10 | 347,599.30 | 6.86 | 5.14 | 8.68 | 6.72 | 61.87 | 62.61 | 14.57 | 11.92 | 0.8436 | 28.21 | 0.2877 | 9.64 | 12.93 | 8.90 | 8.87 | 5.47 | 6.62 | 11.97 |
| Genmab A/S | 1.79bn | 616.35m | 21.72bn | 1.85k | 35.21 | 6.76 | 753.74 | 12.14 | 80.10 | 80.10 | 232.40 | 416.88 | 0.5544 | -- | 5.07 | 9,234,940.00 | 19.10 | 19.27 | 20.31 | 20.51 | -- | -- | 34.46 | 40.71 | -- | -- | 0.0296 | -- | 72.07 | 43.90 | 83.58 | 37.99 | 29.07 | -- |
| HALEON PLC | 11.22bn | 1.11bn | 30.47bn | 21.00k | 27.59 | -- | 71.54 | 2.72 | 0.1196 | 0.1196 | 1.21 | -- | -- | -- | -- | 534,142.90 | -- | -- | -- | -- | 60.83 | -- | 10.49 | -- | -- | 8.15 | -- | -- | 13.76 | -- | -23.74 | -- | -- | -- |
| Lonza Group AG | 5.57bn | 1.09bn | 38.11bn | 17.49k | 35.00 | 4.01 | 23.49 | 6.84 | 16.34 | 16.34 | 83.69 | 142.66 | 0.3681 | 2.28 | 5.95 | 355,722.00 | 7.20 | 5.30 | 8.63 | 6.48 | 39.18 | 39.90 | 19.57 | 15.20 | 1.27 | 21.61 | 0.1731 | 28.41 | 15.05 | 6.47 | 80.27 | 12.84 | 32.93 | 4.94 |
| Bayer AG | 43.87bn | 2.64bn | 46.43bn | 101.74k | 17.60 | 1.31 | 5.60 | 1.06 | 3.09 | 3.09 | 51.39 | 41.60 | 0.4026 | 1.67 | 3.46 | 498,071.40 | 2.44 | -1.11 | 3.30 | -1.45 | 59.54 | 58.98 | 6.05 | -3.04 | 0.7587 | 4.95 | 0.5135 | -- | 15.10 | 7.70 | 315.00 | 5.02 | 4.50 | -2.72 |
| GSK plc | 29.09bn | 4.34bn | 57.01bn | 69.40k | 12.63 | 4.82 | 8.13 | 1.96 | 1.10 | 3.64 | 7.52 | 2.89 | 0.3923 | 1.51 | 3.84 | 419,092.20 | 6.45 | 6.39 | 9.82 | 10.42 | 70.42 | 69.55 | 16.44 | 15.90 | 0.694 | 9.71 | 0.6489 | 93.37 | 18.74 | -0.5778 | 51.73 | 10.27 | 0.5035 | -5.53 |
| Sanofi SA | 40.14bn | 7.26bn | 109.02bn | 91.57k | 14.95 | -- | 11.93 | 2.72 | 6.65 | 6.65 | 36.84 | -- | -- | -- | -- | 504,504.60 | -- | 5.80 | -- | 7.02 | 69.93 | 68.49 | 18.24 | 17.00 | -- | 102.64 | -- | 59.84 | 15.86 | 4.62 | 34.52 | 17.28 | 2.39 | 3.28 |
| Novartis AG | 42.23bn | 5.69bn | 181.11bn | 103.00k | 30.22 | 3.96 | 17.72 | 4.29 | 2.94 | 2.94 | 21.78 | 22.47 | 0.4391 | 2.03 | 6.02 | 464,083.90 | 5.92 | 9.09 | 7.95 | 11.77 | 71.09 | 70.98 | 13.48 | 23.68 | 0.7931 | 12.26 | 0.3586 | 59.94 | -2.15 | 3.60 | -71.05 | -1.49 | 3.09 | 3.79 |
| AstraZeneca plc | 35.52bn | 3.81bn | 182.31bn | 83.50k | 48.14 | 6.29 | 21.68 | 5.13 | 2.44 | 2.44 | 22.77 | 18.71 | 0.4452 | 1.35 | 4.62 | 425,359.10 | 4.78 | 2.63 | 6.31 | 3.62 | 80.63 | 78.99 | 10.74 | 6.35 | 0.6959 | 6.82 | 0.468 | 187.07 | 18.53 | 14.57 | 2,835.71 | 6.63 | 9.68 | 1.13 |
| Roche Holding AG | 56.61bn | 11.11bn | 212.76bn | 103.61k | 18.93 | 8.30 | 13.69 | 3.76 | 15.36 | 15.36 | 78.32 | 35.03 | 0.7013 | 2.27 | 5.65 | 610,743.80 | 15.00 | 16.21 | 25.31 | 25.33 | 70.75 | 71.07 | 21.38 | 22.62 | 0.9256 | 19.25 | 0.4419 | 59.33 | 0.7643 | 3.49 | -10.83 | 7.26 | 2.63 | 2.74 |
| Novo Nordisk A/S | 21.97bn | 7.13bn | 227.95bn | 57.09k | 42.32 | 32.03 | 28.84 | 10.38 | 26.88 | 26.88 | 82.71 | 35.52 | 0.8422 | 1.29 | 4.34 | 3,461,659.00 | 27.34 | 29.83 | 55.67 | 58.58 | 84.22 | 83.76 | 32.47 | 32.86 | 0.6694 | 16.84 | 0.2421 | 45.88 | 25.68 | 9.64 | 16.27 | 7.81 | 11.27 | 9.57 |
Data as of May 26 2023. Currency figures normalised to GSK plc's reporting currency: UK Pound GBX
18.71%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 01 May 2023 | 148.76m | 3.63% |
| BlackRock Fund Advisorsas of 01 May 2023 | 121.21m | 2.96% |
| Dodge & Coxas of 03 Mar 2023 | 99.38m | 2.43% |
| Schroder Investment Management Ltd.as of 01 May 2023 | 69.98m | 1.71% |
| Silchester International Investors LLPas of 01 May 2023 | 66.61m | 1.63% |
| BlackRock Advisors (UK) Ltd.as of 01 May 2023 | 64.47m | 1.57% |
| Legal & General Investment Management Ltd.as of 01 May 2023 | 54.48m | 1.33% |
| Mondrian Investment Partners Ltd.as of 01 May 2023 | 50.97m | 1.25% |
| SSgA Funds Management, Inc.as of 01 May 2023 | 48.89m | 1.19% |
| Threadneedle Asset Management Ltd.as of 01 May 2023 | 41.30m | 1.01% |
More ▼
Data from 31 Mar 2023 - 31 Mar 2023Source: FactSet Research Systems Inc.
